US Scenario Modeling Hub, a collaborative modeling effort of 17 academic research institutions, reports a universal COVID-19 vaccination recommendation could avert thousands more US hospitalizations and deaths than a high-risk-only strategy.
COVID-19 remains a substantial current public health concern in the US, with higher in-hospital mortality than seasonal influenza during fall-winter 2023–2024.
The Advisory Committee on Immunization Practices (ACIP) sets vaccine use guidance and has traditionally been made up of medical and public health experts within the U.S. Centers for Disease Control and Prevention (CDC). The committee is tasked with framing evidence-based recommendations for the use of vaccines that are effective in controlling diseases.
Recently, the committee has undergone a complete turnover of members, removing seasoned experts in favor of political appointments that include a psychiatrist and several individuals that claim vaccines cause disease. Gone are family physicians and pediatric infectious disease specialists, epidemiologists, geriatric medicine specialists, obstetricians and anyone with experience as a public health implementer.
Scenario modeling offers a way to compare potential future outcomes of ACIP decisions and inform policy for public health groups that will no longer rely on ACIP recommendations.
In the study, “Scenario Projections of COVID-19 Burden in the US, 2024-2025,” published in JAMA Network Open, researchers used a decision-analytical model to project national hospitalizations and deaths from April 2024 to April 2025 and to assess the potential benefit of annual vaccine recommendations.
Nine independent teams produced projections under six scenarios that combined two immune escape rates, 20% and 50% per year. An immune escape rate is the annual reduction in protection against infection that occurs as new SARS-CoV-2 variants evolve. Projections covered the United States population of 332 million with an estimated 58 million aged 65 years.
Three vaccine recommendation strategies were tested. No recommendation, recommendation for high-risk groups only, or recommendation for all eligible individuals. Annually reformulated vaccines were assumed to match variants circulating on June 15, 2024, to be available on September 1, 2024, and to be 75% effective against hospitalization at the time of release.
Teams calibrated their models to weekly hospitalizations and deaths reported by the National Healthcare Safety Network and the National Center for Health Statistics.
In the worst case scenario, defined by high immune escape with no vaccine recommendation, projections reached 931,000 hospitalizations with a 95% projection interval of 0.5 to 1.3 million and 62,000 deaths with a 95% projection interval of 18,000 to 115,000.
In the best case defined by low immune escape with a universal recommendation, the ensemble projected 550,000 hospitalizations with a 95% projection interval of 296,000 to 832,000 and 42,000 deaths with a 95% projection interval of 13,000 to 72,000.
Severe outcomes clustered in older populations. Across scenarios, adults aged 65 years and older accounted for 51% to 62% of hospitalizations and 84% to 87% of deaths.
Vaccination of high-risk groups was only projected to avert 11% of hospitalizations under low immune escape and 8% under high escape, along with 13% and 10% of deaths. A universal recommendation increased the effect with 15% fewer hospitalizations under low immune escape and 11% fewer under high, with 16% and 13% fewer deaths.
Under high immune escape, a high-risk-only strategy averted 76,000 hospitalizations with a 95% CI of 34,000 to 118,000 and 7,000 deaths with a 95% CI of 3,000 to 11,000. Expanding to a universal recommendation prevented 104,000 hospitalizations with a 95% CI of 55,000 to 153,000 and 9,000 deaths with a 95% CI of 4,000 to 14,000.
Additional indirect benefits accrued to older adults under a universal strategy. Compared with high-risk-only vaccination, universal recommendations prevented about 11,000 more hospitalizations and 1,000 more deaths in those aged 65 years and older.
Observed national patterns diverged in timing from projections. A marked summer 2024 wave was followed by a smaller peak in January 2025, while projections anticipated the heaviest burden from late December 2024 to mid January 2025. Ensemble coverage for weekly deaths remained strong, with 95% intervals closely matching observed values.
Authors conclude that vaccines remain a critical tool to limit COVID-19 burden in 2024–2025, with universal recommendations offering added direct and indirect protection and the potential to save thousands more lives, including among older adults.
Written for you by our author Justin Jackson, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You’ll get an ad-free account as a thank-you.
More information: Sara L. Loo et al, Scenario Projections of COVID-19 Burden in the US, 2024-2025, JAMA Network Open (2025). DOI: 10.1001/jamanetworkopen.2025.32469
News
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]
3D Human Brain Tissue Model Replicates Alzheimer’s Pathology
Summary: Researchers introduced a highly reproducible three-dimensional human brain tissue model capable of replicating complex neurodegenerative processes in Alzheimer’s disease. Developed over nine years using human stem cells, the self-organizing tissue spheroids integrate functional neurons, [...]
